Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 14:59 ET | Source: Bragar Eagel & Squire

MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Merck allegedly misled investors about Gardasil’s growth and China demand; stock fell nearly 10% in July 2024 and over 9% in February 2025.
August 28, 2025 12:12 ET | Source: Spherix Global Insights

Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights

Exton, Pennsylvania, Aug. 28, 2025 (GLOBE NEWSWIRE) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S....
August 25, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Chemical Reagents Market Size/Share Worth USD 26.5 Billion by 2034 at a 7.5 CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Chemical Reagents Market Size, Trends and Insights By Product Type (Solvents,...
July 19, 2025 14:54 ET | Source: Bragar Eagel & Squire

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options If you purchased or acquired...
July 16, 2025 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or...
April 17, 2025 21:00 ET | Source: Bragar Eagel & Squire

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc....
April 15, 2025 03:00 ET | Source: Cyprumed GmbH

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive up to $493 million in upfront, development, regulatory...
April 09, 2025 10:44 ET | Source: Faruqi & Faruqi LLP

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you...
April 02, 2025 09:55 ET | Source: Faruqi & Faruqi LLP

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Merck To Contact Him Directly To Discuss Their Options If you purchased or...
April 01, 2025 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Intellia, and Merck and Encourages Investors to Contact the Firm

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...